VSTM — Verastem, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1526119 ·
Last close
$7.74
Market Cap
$700.96M
52W High
$10.82
52W Low
$3.43
ADV30
2,208,010
Next earnings
2026-11-03

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 40,078,000 36,037,000 -32,710,000 -34,673,000 206,511,000 136,353,000 156,525,000
Mar 2026 18,671,000 15,620,000 -44,897,000 -36,591,000 227,808,000 165,551,000 146,031,000
Dec 2025 17,535,000 14,643,000 -41,475,000 -32,916,000 246,442,000 204,990,000 189,245,000
Sep 2025 11,242,000 9,282,000 -40,715,000 -98,518,000 176,852,000 137,706,000 192,378,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-162,195,000
Investing CF
$-9,389,000
Financing CF
$143,615,000
CapEx
$-1,345,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.78
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,236,262,000
Inventory
$2,396,000
Receivables
$29,074,000
ST Investments
$16,127,000
EBIT TTM
$-200,406,000
Pretax Income TTM
$-201,882,000
Interest Exp TTM
$1,476,000
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$87,526,000
EBITDA
$-158,647,008
Free Cash Flow
$-103,429,624
Enterprise Value
$610,901,376
Total Cash
$136,352,992
Total Debt
$84,330,000
Shares Out
90,563,441
Trailing EPS
$-2.44
Book Value
$0.93
ROE
-471.2%
ROA
-49.6%
Div Yield
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 30,914,000 -170,129,000 -209,471,000 246,442,000 189,245,000 57,197,000 -137,509,000
Dec 2024 10,000,000 -114,956,000 -130,637,000 101,538,000 130,431,000 -28,893,000 -104,771,000
Dec 2023 0 -92,084,000 -87,367,000 149,718,000 92,344,000 57,374,000 -86,460,000
Dec 2022 2,596,000 -72,937,000 -73,812,000 95,050,000 47,659,000 47,391,000 -63,673,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.75

Max Pain — expiry 2027-03-19 (volume-derived — Yahoo OI feed degraded)

max pain strike: $10.00 · spot: $7.74 · call volume: 48 · put volume: 328
Expected Move to 2027-03-19: ±$5.35 (69.12%) — implied range $2.39 – $13.09 · ATM straddle on $8.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
COLL COLLEGIUM PHARMACEUTICAL, INC $698.41M $22.53 —
SLN Silence Therapeutics plc $694.88M $11.18 —
ANNX Annexon, Inc. $690.07M $3.64 —
IRWD IRONWOOD PHARMACEUTICALS INC $682.44M $4.13 —
PAHC PHIBRO ANIMAL HEALTH CORP $727.09M $34.45 —

News headlines (Yahoo Finance, 1h cache)

Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting
2026-09-24 12:30 · Yahoo
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why
2026-09-08 14:09 · Yahoo
Verastem Oncology to Participate in Upcoming September Investor Conferences
2026-09-02 11:30 · Yahoo
Verastem (VSTM) Stock Sees Fair Value Moves Lower As Analysts Cut Revenue Views
2026-08-25 18:17 · Yahoo
Verastem (VSTM) Q2 2026 Earnings Call Transcript
2026-08-13 23:46 · Yahoo
Verastem Q2 Earnings Call Highlights
2026-08-07 20:04 · Yahoo
Verastem Inc (VSTM) (Q2 2026) Earnings Call Highlights: Strong Revenue Rebound and Strategic ...
2026-08-07 05:10 · Yahoo
Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
2026-07-23 11:30 · Yahoo
RBC Capital Reaffirms Outperform Rating For Verastem (VSTM)
2026-07-15 15:43 · Yahoo
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-02 20:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.